Literature DB >> 23148187

Editorial: Closing sale of innovative treatment options for the treatment of diabetes and metabolic disorders?

Christoph Schindler.   

Abstract

Entities:  

Year:  2011        PMID： 23148187      PMCID： PMC3474642          DOI： 10.1177/2042018811430839

Source DB:  PubMed          Journal:  Ther Adv Endocrinol Metab        ISSN： 2042-0188            Impact factor:   3.565


× No keyword cloud information.
  24 in total

1.  Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20).

Authors:  Erland Erdmann; Robert Spanheimer; Bernard Charbonnel
Journal:  J Diabetes       Date:  2010-09       Impact factor: 4.006

2.  Collateral damage: the conundrum of drug safety.

Authors:  E A M Gale
Journal:  Diabetologia       Date:  2009-10       Impact factor: 10.122

3.  Glycemic status and development of kidney disease: the Framingham Heart Study.

Authors:  Caroline S Fox; Martin G Larson; Eric P Leip; James B Meigs; Peter W F Wilson; Daniel Levy
Journal:  Diabetes Care       Date:  2005-10       Impact factor: 19.112

4.  Insulin analogues and cancer risk: the emergence of second-generation studies.

Authors:  A G Renehan
Journal:  Diabetologia       Date:  2011-10-28       Impact factor: 10.122

5.  Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.

Authors:  W Philip T James; Ian D Caterson; Walmir Coutinho; Nick Finer; Luc F Van Gaal; Aldo P Maggioni; Christian Torp-Pedersen; Arya M Sharma; Gillian M Shepherd; Richard A Rode; Cheryl L Renz
Journal:  N Engl J Med       Date:  2010-09-02       Impact factor: 91.245

Review 6.  Diabetes and pancreatic cancer: chicken or egg?

Authors:  J Trent Magruder; Dariush Elahi; Dana K Andersen
Journal:  Pancreas       Date:  2011-04       Impact factor: 3.327

7.  Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.

Authors:  Michael Elashoff; Aleksey V Matveyenko; Belinda Gier; Robert Elashoff; Peter C Butler
Journal:  Gastroenterology       Date:  2011-02-18       Impact factor: 22.682

8.  Combined randomised controlled trial experience of malignancies in studies using insulin glargine.

Authors:  P D Home; P Lagarenne
Journal:  Diabetologia       Date:  2009-09-15       Impact factor: 10.122

9.  The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.

Authors:  C J Currie; C D Poole; E A M Gale
Journal:  Diabetologia       Date:  2009-07-02       Impact factor: 10.122

10.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Authors:  Steven E Nissen; Kathy Wolski
Journal:  N Engl J Med       Date:  2007-05-21       Impact factor: 91.245
View more
  1 in total

1.  [Benefits and risks of current pharmacotherapy in the treatment of type 2 diabetes].

Authors:  C Schindler; A Barthel; S Fischer; S R Bornstein; W Kirch
Journal:  Internist (Berl)       Date:  2012-04       Impact factor: 0.743
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.